GSK AVRORA, OOO, Krasnodar Krai

Economic indicators

Net profit (RAS) of GSK AVRORA, OOO dropped in 2023 2.30 times to 15.24 million RUB from 35.12 million RUB over the same period in 2022, the company informed.

Revenue decreased in the accounting period by 45.76% to 167.49 million RUB from 308.81 million RUB in 2022.

Net profit (RAS) of GSK AVRORA, OOO grew over 2022 42.26 times to 35.12 million RUB from 831.00 thousand RUB over 2021, the company informed.

Revenue increased in the accounting period by 32.70% to 308.81 million RUB from 232.71 million RUB over 2021.

Net profit (RAS) of GSK AVRORA, OOO dropped in 2021 10.43 times to 831.00 thousand RUB from 8.67 million RUB over the same period in 2020, the company informed.

Revenue decreased in the accounting period by 32.14% to 232.71 million RUB from 342.94 million RUB in 2020.

Net profit (RAS) of GSK AVRORA, OOO dropped in 2020 by 36.31% to 8.67 million RUB from 13.61 million RUB over the same period in 2019, the company informed.

Revenue decreased in the accounting period 2.81 times to 342.94 million RUB from 963.51 million RUB in 2019.

Net profit (RAS) of GSK AVRORA, OOO grew over 2019 3.15 times to 13.61 million RUB from 4.33 million RUB over 2018, the company informed.

Revenue increased in the accounting period by 48.48% to 963.51 million RUB from 648.92 million RUB over 2018.

Net profit (RAS) of GSK AVRORA, OOO dropped in 2018 by 26.85% to 4.33 million RUB from 5.92 million RUB over the same period in 2017, the company informed.

Revenue increased in the accounting period 2.30 times to 648.92 million RUB from 281.77 million RUB over 2017; cost of goods sold grew 1.84 times to 623.80 million RUB from 339.54 million RUB; sales profit made up 25.11 million RUB compared to sales loss of 57.77 million RUB.

Companies in the region

• ESMIRAL'DA
• EVROINERT
• DARUM
• YUMK
• SAPFIR